We have updated the pathway: Tamoxifen PK pathway.
Tamoxifen is a selective estrogen receptor modulator. It is used to treat estrogen receptor positive breast cancer, and has been shown to decrease disease recurrence and mortality rates by 50% and 30%, respectively.
PharmGKB's Tamoxifen PK pathway describes the metabolism of tamoxifen from what can be classified as a pro-drug, to a more potent estrogen receptor inhibitor, and finally to its inactivation.
View or download the pathway here: Tamoxifen PK pathway.
View all pathways at PharmGKB.
